Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | TYMS | P04818 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19328559 | 0.99 | PNP (0.46) | PNPTYMS | |
| Hydrochloric Acid SCHEMBL19253833 | 0.99 | PNP (0.46) | PNPTYMS | |
| SCHEMBL17652055 | 0.95 | PNP (0.45) | PNPTYMS | |
| Hydrochloric Acid SCHEMBL19253840 | 0.94 | PNP (0.44) | PNPTYMS | |
| SCHEMBL19929245 | 0.92 | PNP (0.48) | PNPTYMS | |
| SCHEMBL19270445 | 0.86 | PNP (0.36) | PNP | |
| SCHEMBL19275108 | 0.84 | XDH (0.38) | PNP | |
| SCHEMBL17652074 | 0.82 | TYMS (0.48) | PNPTYMS | |
| SCHEMBL21161374 | 0.82 | TYMS (0.49) | TYMS | |
| Hydrochloric Acid SCHEMBL17652090 | 0.81 | TYMS (0.48) | PNPTYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3201198-B1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST FELLOWS FOUND SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIV (IE) | 2020-07-29 | — | — | EP | claimed |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | AMABIOTICS (FR) | 2023-06-27 | — | — | US | disclosed |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | AMABIOTICS (FR) | 2023-06-27 | — | — | US | disclosed |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | AMABIOTICS (FR) | 2023-06-27 | — | — | US | disclosed |
| CN-110035758-B | Compounds for the treatment of diseases associated with mitochondrial dysfunction | AMA生物制药公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20230040247-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | AMABIOTICS (FR) | 2023-02-09 | — | — | US | disclosed |
| US-20230040247-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | AMABIOTICS (FR) | 2023-02-09 | — | — | US | disclosed |
| US-11518765-B2 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | THE PROVOST, THE FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2022-12-06 | — | — | US | disclosed |
| US-11518765-B2 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | THE PROVOST, THE FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2022-12-06 | — | — | US | disclosed |
| EP-4028014-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | Stellate Therapeutics (FR) | 2022-07-20 | — | — | EP | disclosed |
| US-20190224174-A1 | COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH A MITOCHONDRIAL DYSFUNCTION | AMABIOTICS (FR) | 2019-07-25 | — | — | US | disclosed |
| EP-3200798-B1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST FELLOWS FOUND SCHOLARS & THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY & UNDIV T (IE) | 2019-05-22 | — | — | EP | disclosed |
| WO-2018041919-A1 | COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH A MITOCHONDRIAL DYSFONCTION | AMABIOTICS (FR) | 2018-03-08 | — | — | WO | disclosed |
| US-20170258797-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-09-14 | — | — | US | disclosed |
| US-20170258797-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-09-14 | — | — | US | disclosed |
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST FELLOWS FOUNDATION SCHOLARS AND THE OTHER MEMBERS OF BOARD OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH (IE) | 2017-08-24 | — | — | US | disclosed |
| WO-2016050804-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016050806-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240553-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE DISEASES | TYMS, DPYD, C5 | PNP 66/4885TYMS 1/4885 |
| US-11518765-B2 | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | TYMS, C5, HRH3 | PNP 109/4885TYMS 1/4885 |
| US-20230040247-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | PNP 3067/4885TYMS 4634/4885 |
| US-20190224174-A1 | COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH A MITOCHONDRIAL DYSFUNCTION | NDUFAB1, FH, TFAM | PNP 2691/4885TYMS 3412/4885 |
| US-20170258797-A1 | TREATMENTS FOR AUTOIMMUNE DISEASE | QTRT1, QTRT2, HPRT1 | PNP 67/4885TYMS 20/4885 |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | NDUFAB1, FH, TFAM | PNP 2691/4885TYMS 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.